Eurobio Scientific

FISCAL YEAR 2023, STRATEGIC TRANSFORMATION OF THE GROUP

FISCAL YEAR 2023, STRATEGIC TRANSFORMATION OF THE GROUP

• Continued total year growth in core business revenues, up 39%
• Successful deployment of the Group's strategy:
  • Proprietary products up at 30% of revenues
  • Internationalization, with 38% of revenues now generated outside of France
• Acquisition of DID in Italy effective as of July 1^st, 2023
• Acquisition of Alpha Biotech, GenDx distributor, effective as of January 3^rd, 2024

Paris, January 30, 2024 – 5:45 pm

Eurobio Scientific (FR0013240934, ALERS, PEA-PME eligible), a leading French group in in vitro specialty medical diagnostics and life sciences, today presents its consolidated annual revenues for the period ending December 31, 2023.

Strong growth of core business at +39%

Eurobio Scientific recorded revenues of €130.1 million for its core business at the end of 2023. Activities linked to the detection of COVID are now integrated to the core business (respiratory panels) and represent approximately €6 million for 2023.
In 2022, the Group generated sales of €152.6 million. Excluding non-recurring sales from the COVID business (€59.1m), growth for 2023 therefore reached +39%.

On a comparable proforma basis, i.e. excluding perimeter effects linked to acquisitions and non-recurring items, growth of the core business remained dynamic, at +12%.

in €m		H1 2022					2023	change. / core	at constant scope
		TOTAL	COVID		core
Revenues		152.6	59.1		93.5		130.1	+39%	+12%
unaudited

Successful deployment of the Group's strategy

The Group is successfully pursuing its strategy of targeted geographic and technological expansion, with the ambition of becoming a major international company in the specialty diagnostics market, providing its customers with a comprehensive molecular diagnostics offering, including its own solutions and those of its partners.

• Share of proprietary products at 30% of revenues
  
  

The share of proprietary products represents 30% of revenues (compared to 18% of core revenues in 2022), thanks in particular to the contribution of GenDx, consolidated in the Group's financial statements as of October 1^st, 2022.